- Home
- TWIN vs ABOS Comparison
TWIN vs ABOS Comparison
Compare TWIN & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TWIN | ABOS |
|---|---|---|
| Founded | 1918 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 320.9M | 197.9M |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TWIN | ABOS |
|---|---|---|
| Price | $26.13 | $2.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 71.6K | ★ 332.9K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.98% | N/A |
| EPS Growth | ★ 1428.57 | N/A |
| EPS | ★ 1.86 | N/A |
| Revenue | ★ $381,270,000.00 | N/A |
| Revenue This Year | $10.79 | N/A |
| Revenue Next Year | $8.43 | N/A |
| P/E Ratio | $13.95 | ★ N/A |
| Revenue Growth | ★ 11.90 | N/A |
| 52 Week Low | $13.42 | $1.45 |
| 52 Week High | $26.18 | $3.60 |
Technical Indicators
Market Signals| Indicator | TWIN | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 66.82 | 33.18 |
| Support Level | $22.13 | $2.13 |
| Resistance Level | N/A | $2.42 |
| Average True Range (ATR) | 0.91 | 0.20 |
| MACD | 0.19 | -0.09 |
| Stochastic Oscillator | 86.08 | 1.40 |
Price Performance
Historical ComparisonAbout TWIN Twin Disc Incorporated
Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its product portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.